What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
Entyce is a flavored oral solution that is used to stimulate appetite in dogs. It is a tasty appetite stimulant that can help treat both chronic and acute conditions in dogs that cause a decrease in appetite. Entyce 30 mg/ml oral solution is available as 10 ml, 15 ml, and 30 ml bottles that come with a convenient dosing syringe for quicker and more accurate administration.
Entyce contains capromorelin, which mimics the hunger hormone (ghrelin) in the brain that generates the feeling of hunger.
ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.
ENTYCE provides a convenient, once-daily oral solution for treating inappetence. Please reference the chart for recommended dosages.
To administer ENTYCE, the bottle should be shaken gently and then the appropriate amount of solution withdrawn using the provided syringe. The syringe should be rinsed between treatment dose.1
|Weight of Dog||Dose|
Field Study The clinical Field Study1 demonstrated a significantly higher proportion of inappetent dogs that received ENTYCE® (carpromorelin oral solution) had increased appetite as comparerd to dogs that received placebo.
PRIMARY ENDPOINT: Owner Appetite Assessment
|Treatment success-single-question assessment %*||68.6||44.6||0.0078|
|Treatment success-Owner Appetite Assessment, %†||56.2||26.8||0.0071|
|Percent change in body weight, mean (SD)||1.83(2.8)||0.11(3.61)||0.004|
|Percent change in Owner Appetite Assessment, mean (SD)||73.4(75.9)||35.6(53.9)||0.0125|
*A dog was considered a treatment success if the owner answered that their dog's appetite was increased in response to the question,"Do you feel that during the study (over the 4± 1 days of treatment) your dog's appetite was increased, no change or decreased?"†Treatment success was defined as an increase in total score? 5 from day 0 to day 3 ± 1 (scoring scale 5-25)
|Adverse Reactions*||ENTYCE (n=171)* n(%)||Placebo (n=73)* n(%)|
|Diarrhea||12 (7.0%)||5 (6.8%)|
|Vomiting||11 (6.4%)||4 (5.5%)|
|Elevated blood urea nitrogen (BUN)||7 (4.1%)||2 (2.7%)|
|Polydipsia||7 (4.1%)||1 (1.4%)|
|Elevated phosphorus||4 (2.3%)||1 (1.4%)|
|Hypersalivation||4 (2.3%)||0 (0.0%)|
|Abdominal discomfort||2 (1.2%)||0 (0.0%)|
|Flatulence||2 (1.2%)||0 (0.0%)|
|Lethargy/depression||2 (1.2%)||0 (0.0%)|
|Nausea||2 (1.2%)||0 (0.0%)|
|Elevated creatinine||1 (0.6%)||1 (1.4%)|
*The following adverse reactions were reported in < 1% of dogs that were administered ENTYCe: hyperractivity, increased fecal volume, increased gut sounds and polyuria.
CONCLUSION This study demonstrates that a ghrelin receptor agonist, ENTYCE, can stimulate appetite and increase body weight in a large population of client-owned dogs with reduced appetite of varying etiologies and was well-tolerated.
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.
Not for use in humans. Keep this and all medications out of reach of children and pets.Consult a physician in case of accidental ingestion by humans. For use in dogs only
Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology).
Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).
The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.